Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Increvet Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action. This 1 outstanding response suggests a narrow interaction with the patent office. The concentration of work is further reflected in the involvement of 1 distinct examiner and 1 distinct art unit, indicating that the pending intellectual property is situated within a specific technical niche.
The busiest examiner for the portfolio is SASAN, ARADHANA, who is responsible for 1 busiest examiner pending office action. Because this examiner handles the only pending action, the prosecution strategy is currently dependent on the review of 1 individual. This alignment between the total 1 pending office action and the 1 distinct examiner ensures that the company's immediate legal efforts are focused on 1 point of contact within the USPTO. The presence of 1 distinct art unit confirms that the subject matter has not branched into diverse regulatory or technical classifications at this stage.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18318133 | VETERINARY PHARMACEUTICAL FORMULATIONS | SASAN, ARADHANA | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18318133 | VETERINARY PHARMACEUTICAL FORMULATIONS | SASAN, ARADHANA | 1615 | §103Other | Non-Final OA | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIncrevet Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aradhana Sasan has the most, with 1 of Increvet Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
